Table 1 Baseline characteristics of the included participants, n = 91
Control group n = 30 | Non-individualised intervention n = 28 | Individualised intervention n = 33 | Total sample n = 91 | |
|---|---|---|---|---|
Gender n (%) Male/female | 21 (67.7)/9 (30.0) | 15 (54.6)/13 (46.4) | 23 (69.7)/10 (30.3) | 59 (64.8)/32 (35.2) |
Age median (min–max) Months | 3.3 (0.2–22.4) | 2.9 (0.5–22.2) | 2.1 (0.3–23.7) | 2.5 (0.2-23.7) IQRa 1.2, 6.9 |
Infectious agent n (%)b | ||||
RSVc | 18 (60.0) | 19 (67.9) | 22 (66.7) | 59 (64.8) |
Influenza | 2 (6.7) | 3 (10.7) | 4 (12.1) | 9 (9.9) |
Other | 1 (3.3) | 3 (10.7) | 3 (9.1) | 7 (7.7) |
Negative | 5 (16.6) | 1 (3.6) | 1 (3.0) | 7 (7.7) |
Missing | 5 (16.6) | 2 (7.1) | 4 (12.1) | 11 (12.1) |
Heredity atopic disease n (%) | ||||
Asthma | 10 (33.3) | 10 (35.7) | 12 (36.4) | 32 (35.2) |
Other (allergies, eczema etc.) | 7 (23.3) | 5 (17.9) | 11 (33.3) | 23 (25.3) |
None | 10 (33.3) | 10 (35.7) | 3 (9.1) | 23 (25.3) |
Missing | 3 (10.0) | 3 (10.7) | 7 (21.2) | 13 (14.3) |
Passive smoking exposure n (%) | ||||
No | 22 (73.3) | 21 (75.0) | 17 (51.6) | 60 (65.9) |
Yes | 5 (16.6) | 3 (10.7) | 8 (24.2) | 16 (17.6) |
Missing | 3 (10.0) | 4 (14.3) | 8 (24.2) | 15 (16.5) |